Results 271 to 280 of about 56,186 (320)
Some of the next articles are maybe not open access.
American Journal of Clinical Oncology, 1995
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
Pharmacogenetics of Aromatase Inhibitors
Pharmacogenomics, 2012Aromatase inhibitors (AIs) are an important class of endocrine drugs used in the treatment of early and advanced breast cancer in postmenopausal women. A number of studies have taken candidate approaches to assess the role of variants in genes encoding enzymes important in AI metabolism, notably CYP19A1 (aromatase), in AI response.
Hadfield, Kristen D., Newman, William G.
openaire +3 more sources
Aromatase inhibitors—Socioeconomical issues
The Journal of Steroid Biochemistry and Molecular Biology, 2005Novel, third-generation aromatase inhibitors are currently implemented for treatment of postmenopausal breast cancer in the metastatic and adjuvant setting and, potentially, for breast cancer prevention. Introduction of novel therapeutic strategies to large patient groups may add significant costs to health care budgets, forcing institutions to focus ...
Per E, Lønning, Jürgen, Geisler
openaire +3 more sources
Expert Opinion on Therapeutic Patents, 2002
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources
Aromatase, Aromatase Inhibitors, and Breast Cancer
American Journal of Therapeutics, 2001Estrogens are involved in numerous physiologic processes and have crucial roles in particular disease states, such as mammary carcinomas. Estradiol, the most potent endogenous estrogen, is biosynthesized from androgens by the cytochrome P-450 enzyme complex called aromatase.
openaire +2 more sources
Arthralgia and aromatase inhibitors
Joint Bone Spine, 2014Joint Bone Spine - In Press.Proof corrected by the author Available online since mercredi 14 aout ...
Daniel, Wendling +4 more
openaire +2 more sources
Bulletin du cancer, 1999
Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone. Two classes have been described: steroidal inhibitors which act competitively and irreversibly and non steroidal inhibitors which block the P 450 cytochrome. The first one is aminoglutethimide
M L, Feutrie, J, Bonneterre
openaire +1 more source
Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone. Two classes have been described: steroidal inhibitors which act competitively and irreversibly and non steroidal inhibitors which block the P 450 cytochrome. The first one is aminoglutethimide
M L, Feutrie, J, Bonneterre
openaire +1 more source
The Journal of Steroid Biochemistry and Molecular Biology, 1999
Inhibitors of aromatase (estrogen synthetase) have been developed as treatment for postmenopausal breast cancer. Both steroidal substrate analogs, type I inhibitors, which inactivate the enzyme and non-steroidal competitive reversible, type II inhibitors, are now available.
A, Brodie, Q, Lu, B, Long
openaire +2 more sources
Inhibitors of aromatase (estrogen synthetase) have been developed as treatment for postmenopausal breast cancer. Both steroidal substrate analogs, type I inhibitors, which inactivate the enzyme and non-steroidal competitive reversible, type II inhibitors, are now available.
A, Brodie, Q, Lu, B, Long
openaire +2 more sources
Aromatase inhibitors for chemoprevention
Best Practice & Research Clinical Endocrinology & Metabolism, 2004Pre-clinical, molecular and epidemiological evidence supports a role for estrogen in both the initiation and promotion of breast cancer. Antagonizing estrogen has therefore been proposed as one way of reducing risk. Tamoxifen, which competes with estrogen at the estrogen receptor, has been shown in four phase III clinical trials to reduce tumour ...
Paul E, Goss, Kathrin, Strasser-Weippl
openaire +2 more sources
Aromatase inhibitors: Future directions
The Journal of Steroid Biochemistry and Molecular Biology, 2005Estrogen and its cognate estrogen receptor are key players in the etiology and progression of breast cancer. Aromatase inhibitors, suppressing tumor and plasma estrogen levels by blocking testosterone conversion to estrogen, have been proven to provide the most effective endocrine therapy for postmenopausal breast cancer patients.
C Kent, Osborne, Rachel, Schiff
openaire +2 more sources